13.80
Viridian Therapeutics Inc stock is traded at $13.80, with a volume of 525.26K.
It is up +5.37% in the last 24 hours and down -9.34% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$13.13
Open:
$13.34
24h Volume:
525.26K
Relative Volume:
0.56
Market Cap:
$1.04B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-3.247
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
+8.09%
1M Performance:
-9.34%
6M Performance:
-43.39%
1Y Performance:
-3.25%
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VRDN
Viridian Therapeutics Inc
|
13.80 | 1.04B | 288.00K | -228.06M | -168.82M | -4.25 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.62 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.71 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
600.69 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.00 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.42 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Nov-25-24 | Initiated | TD Cowen | Buy |
Sep-11-24 | Reiterated | Needham | Buy |
Jun-11-24 | Initiated | Wolfe Research | Outperform |
Jun-06-24 | Initiated | Goldman | Buy |
May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Jun-14-23 | Initiated | BTIG Research | Buy |
Jun-14-23 | Resumed | Credit Suisse | Outperform |
May-30-23 | Initiated | RBC Capital Mkts | Outperform |
Apr-17-23 | Initiated | Wells Fargo | Overweight |
Mar-30-23 | Initiated | Stifel | Buy |
Dec-19-22 | Initiated | Cowen | Outperform |
Dec-19-22 | Initiated | Needham | Buy |
Dec-16-22 | Initiated | Credit Suisse | Outperform |
Dec-01-22 | Initiated | H.C. Wainwright | Buy |
Jun-23-22 | Initiated | B. Riley Securities | Buy |
Nov-18-21 | Initiated | SVB Leerink | Outperform |
Oct-12-21 | Initiated | Evercore ISI | Outperform |
Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co. - Defense World
Geode Capital Management LLC Has $31.81 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
Sector Update: Health Care - TradingView
Graves Ophthalmopathy Therapeutics Market Size in 7MM - openPR.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Lifted by Vanguard Group Inc. - Defense World
American Century Companies Inc. Has $2.18 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
KLP Kapitalforvaltning AS Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - BioSpace
Viridian Therapeutics Appoints Jeff Ajer to Board - TipRanks
Viridian Therapeutics appoints Jeff Ajer to board - Investing.com
Viridian Therapeutics appoints Jeff Ajer to board By Investing.com - Investing.com UK
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Corebridge Financial Inc. - Defense World
Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com Canada
(VRDN) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Financial Analysis: Viridian Therapeutics (NASDAQ:VRDN) versus ACI Global (OTCMKTS:ACGJ) - Defense World
Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World
Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World
Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK
Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa
Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq
Viridian Therapeutics appoints new director, sees board resignation - Investing.com India
What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World
Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com
Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa
Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com
Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks
Viridian Therapeutics inks new $300M sales agreement - Investing.com
Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks
Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView
Q1 EPS Estimates for Viridian Therapeutics Raised by Wedbush - Defense World
How to Take Advantage of moves in (VRDN) - Stock Traders Daily
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viridian Therapeutics Inc Stock (VRDN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mahoney Stephen F. | President and CEO |
Sep 27 '24 |
Buy |
23.33 |
21,400 |
499,262 |
21,400 |
Fairmount Funds Management LLC | Director |
Sep 13 '24 |
Buy |
18.75 |
1,600,000 |
30,000,000 |
3,445,813 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):